iBio, Inc. | Business Contracts

Asset Purchase Agreement, dated September 16, 2022, by and between iBio, Inc. and Rubryc Therapeutics, Inc (Filed With SEC on September 21, 2022)

Form of Irrevocable Proxy For Voting Control (Filed With SEC on May 12, 2022)

Third Amendment to Exclusive License Agreement, dated February 3, 2022, by and between University of Pittsburgh and iBio, Inc (Filed With SEC on May 12, 2022)

Consulting Agreement with Randy J. Maddux (Filed With SEC on May 2, 2022)

Environmental Indemnity Agreement, dated November 1, 2021 by iBio CDMO LLC and iBio, Inc. in favor of Woodforest National Bank (Filed With SEC on November 4, 2021)

Form of Stock Purchase Agreement (Filed With SEC on May 12, 2022)

Security Agreement, dated November 1, 2021by iBio CDMO LLC for the benefit of Woodforest National Bank (Filed With SEC on November 4, 2021)

Leasehold Deed of Trust, Assignment of Leases and Rents, Security Agreement and UCC Financing Statement for Fixture Filing by iBio CDMO LLC as grantor to the trustee for the... (Filed With SEC on November 4, 2021)

Guaranty Agreement, dated November 1, 2021, by iBio, Inc. for the benefit of Woodforest National Bank (Filed With SEC on November 4, 2021)

Credit Agreement, dated November 1, 2021 by and, between iBio CDMO LLC with Woodforest National Bank (Filed With SEC on November 4, 2021)

Equity Purchase Agreement dated November 1, 2021 by and between Bryan Capital Investors LLC and iBio, Inc (Filed With SEC on November 4, 2021)

Purchase and Sale Agreement, dated November 1, 2021, by and among College Station Investors LLC, Bryan Capital Investors LLC, iBio CDMO LLC and iBio, Inc (Filed With SEC on November 4, 2021)

iBio, Inc. Warrant (Filed With SEC on November 4, 2021)

Term Note of iBio CDMO LLC (Filed With SEC on November 4, 2021)

Description of Securities of iBio, Inc (Filed With SEC on September 28, 2021)

Confidential Settlement and Mutual Release with Fraunhofer USA, Inc. dated May 4, 2021 (Filed With SEC on September 28, 2021)

Employment Agreement dated January 18, 2021, by and between iBio, Inc. and Martin B. Brenner (Filed With SEC on September 28, 2021)

Second Amended and Restated Right of First Refusal and Co-Sale Agreement, dated August 23, 2021, by and among RubrYc Therapeutics, Inc. and certain investors (Filed With SEC on August 27, 2021)

Second Amended and Restated Voting Agreement, dated August 23, 2021, by and among RubrYc Therapeutics, Inc. and certain investors (Filed With SEC on August 27, 2021)

Second Amended and Restated Investor Rights Agreement, dated August 23, 2021, by and among RubrYc Therapeutics, Inc. and certain investors (Filed With SEC on August 27, 2021)

Stock Purchase Agreement, dated August 23, 2021, by and between iBio, Inc. and RubrYc Therapeutics, Inc (Filed With SEC on August 27, 2021)

Collaboration and License Agreement, dated August 23, 2021, by and between iBio, Inc. and RubrYc Therapeutics, Inc (Filed With SEC on August 27, 2021)

Collaboration, Option and License Agreement, dated August 23, 2021, by and between iBio, Inc. and RubrYc Therapeutics, Inc (Filed With SEC on August 27, 2021)

Director Offer Letter (Filed With SEC on August 26, 2021)

Director Offer Letter (Filed With SEC on June 9, 2021)

Employment Agreement, dated as of April 30, 2021, by and between iBio, Inc. and Thomas F. Isett (Filed With SEC on May 6, 2021)

Employment Agreement dated February 15, 2021 by and between iBio, Inc. and Robert Lutz, Effective March 4, 2021 (Filed With SEC on February 16, 2021)

Second Amendment to Exclusive License Agreement between the Company and the University of Pittsburgh dated December 2, 2020 (Filed With SEC on February 16, 2021)

First Amendment to Exclusive License Agreement between the Company and the University of Pittsburgh dated August 11, 2016 (Filed With SEC on February 16, 2021)

Exclusive License Agreement between the Company and University of Pittsburgh dated January 14, 2014 (Filed With SEC on February 16, 2021)

Underwriting Agreement, dated December 8, 2020, between iBio, Inc. and Cantor Fitzgerald & Co (Filed With SEC on December 9, 2020)

Employment Agreement dated October 30, 2020 by and between iBio, Inc. and Randy J. Maddux, effective December 1, 2020 (Filed With SEC on November 3, 2020)

Description of Securities of iBio, Inc (Filed With SEC on October 13, 2020)

Indemnification Agreement by and between iBio, Inc., John Delta and TechCXO, LLC dated July 13, 2020 (Filed With SEC on October 5, 2020)

Consulting Agreement by and between iBio, Inc. and TechCXO, LLC, dated July 8, 2020 (Filed With SEC on October 5, 2020)

Amendment No. 1 to Equity Distribution Agreement, dated July 29, 2020, by and between iBio, Inc. and UBS Securities LLC (Filed With SEC on July 29, 2020)

Equity Distribution Agreement, dated June 17 2020, by and between iBio, Inc. and UBS Securities, LLC (Filed With SEC on June 17, 2020)

Form of Stock Option Agreement (Filed With SEC on June 17, 2020)

Transition Agreement, dated June 12, 2020, between Robert Kay and iBio, Inc (Filed With SEC on June 17, 2020)

Purchase Agreement, dated as of May 13, 2020, between iBio, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on May 14, 2020)

Amended and Restated Executive Employment Agreement, dated as of April 21, 2020, between iBio, Inc. and Thomas F. Isett (Filed With SEC on April 27, 2020)

Purchase Agreement, dated March 19, 2020, between the Company and Lincoln Park Capital Fund, LLC (Filed With SEC on March 20, 2020)

Registration Rights Agreement, dated March 19, 2020, between the Company and Lincoln Park Capital Fund, LLC (Filed With SEC on March 20, 2020)

Master Joint Development Agreement, dated as of August 8, 2018, between the Company and Beijing CC-Pharming Ltd (Filed With SEC on March 19, 2020)

Employment Agreement, dated as of March 10, 2020, between iBio, Inc. and Thomas F. Isett (Filed With SEC on March 13, 2020)

Statement of Work 2, dated February 6, 2020, between the Company and Beijing CC-Pharming Ltd (Filed With SEC on March 13, 2020)

Master Joint Development Agreement, dated as of August 8, 2018, between the Company and Beijing CC-Pharming Ltd (Filed With SEC on March 13, 2020)

Form of Amended and Restated Series A Warrant to Purchase Common Stock (Filed With SEC on February 21, 2020)

Warrant Exchange and Amendment Agreement, between the Company and certain Holders, dated February 20, 2020 (Filed With SEC on February 21, 2020)

Form of Amended and Restated Series B Warrant to Purchase Common Stock (Filed With SEC on February 21, 2020)

Form of Promissory Note (Filed With SEC on February 21, 2020)

Underwriting Agreement, dated October 25, 2019, by and between iBio, Inc. and A.G.P./Alliance Global Partners (Filed With SEC on October 29, 2019)

Underwriting Agreement, dated October 25, 2019, by and between iBio, Inc. and A.G.P./Alliance Global Partners (Filed With SEC on October 28, 2019)

Form of Leak-Out Agreement (Filed With SEC on October 28, 2019)

Form of Series B Warrant to Purchase Common Stock (Filed With SEC on October 28, 2019)

Form of Series A Warrant to Purchase Common Stock (Filed With SEC on October 28, 2019)

Form of Leak-Out Agreement (Filed With SEC on October 24, 2019)

Form of Underwriting Agreement (Filed With SEC on October 24, 2019)

Form of Series B Warrant to Purchase Common Stock (Filed With SEC on October 15, 2019)

Form of Series A Warrant to Purchase Common Stock (Filed With SEC on October 15, 2019)

Form of Underwriting Agreement (Filed With SEC on October 15, 2019)

2018 Omnibus Equity Incentive Plan, effective December 18, 2018 (Filed With SEC on August 26, 2019)

Form of Indemnification Agreement (Filed With SEC on April 1, 2019)

iBio, Inc. (63)